NCT02457520View on ClinicalTrials.gov

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

PHASE4CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

January 21, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Acne
Interventions
DRUG

Isotretinoin

ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks

Trial Locations (1)

78218

Texas Dermatology and Laser Specialists, San Antonio

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02457520 - ABSORICA in Patients With Severe Recalcitrant Nodular Acne | Biotech Hunter | Biotech Hunter